Reply To: Destiny Pharma

#5961
Nick Hargrave
Keymaster

https://www.londonstockexchange.com/news-article/DEST/clinical-development-update/16310920

Good news that XF-73 dermal is moving towards the clinic. The real value catalyst remains a commercial deal for XF-73